نتایج جستجو برای: complement dependent lymphocytotoxicity (cdc)

تعداد نتایج: 759890  

Journal: :iranian journal of allergy, asthma and immunology 0
hamid nawaz tipu department of immunology, armed forces institute of pathology, rawalpindi, pakistan muhammad mukarram bashir department of immunology, armed forces institute of pathology, rawalpindi, pakistan muhammad noma department of immunology, armed forces institute of pathology, rawalpindi, pakistan

serology and dna techniques are employed for human leukocyte antigen (hla) typing in different transplant centers. results may not always correlate well and may need retyping with different technique. all the patients (with aplastic anemia, thalassemia, and immunodeficiency) and their donors, requiring hla typing for bone marrow transplant were enrolled in the study. serological hla typing was ...

Journal: :Annals of clinical and laboratory science 1985
R Patel A Soriano L Loeb M Ghoneum D Najera

Monoclonal antisera against helper (serum OKT4) and suppressor (serum OKT8) T cells were employed in a complement-dependent lymphocytotoxicity reaction to isolate helper and suppressor T cells from peripheral blood mononuclear cells. When prepared by this method, helper and suppressor T cells had a purity of 67.8 percent and 78.8 percent, respectively. Approximately 56 percent of viable suppres...

Journal: :British medical journal 1971
R C Nairn A P Nind E P Guli D J Davies J M Rolland A R McGiven E S Hughes

Sixty cases of colonic carcinoma have been investigated for antitumour immunoreactivity. The tests employed were blood lymphocyte reactivity and complement-dependent serum cytotoxicity against cultured tumour cells, and immunofluorescence for membrane staining of viable tumour cells and cytoplasmic staining of dried tumour cells in films. Nineteen cases were positive by one or more tests and th...

2017
Mark T. Winkler Ryan T. Bushey Elizabeth B. Gottlin Michael J. Campa Eross S. Guadalupe Alicia D. Volkheimer J. Brice Weinberg Edward F. Patz

Rituximab therapy for B cell chronic lymphocytic leukemia (B-CLL) has met with mixed success. Among several factors to which resistance can be attributed is failure to activate complement dependent cytotoxicity (CDC) due to protective complement regulatory proteins, including the soluble regulator complement factor H (CFH). We hypothesized that rituximab killing of non-responsive B-CLL cells co...

Journal: :Journal of immunology 2005
Govind Ragupathi Nancy X Liu Cristina Musselli Shemeeakah Powell Kenneth Lloyd Philip O Livingston

One of several effector mechanisms thought to contribute to Ab efficacy against cancer is complement-dependent cytotoxicity (CDC). Serological analysis of a series of clinical trials conducted over a 10-year period suggested that six vaccines containing different glycolipids induced Abs mediating CDC whereas four vaccines containing carbohydrate or peptide epitopes carried almost exclusively by...

Journal: :Journal of immunology 2012
Dana Gancz Michal Lusthaus Zvi Fishelson

Nucleated cells are equipped with several mechanisms that support their resistance to complement-dependent cytotoxicity (CDC). The role of the NF-κB pathway in cell protection from CDC was examined. Elevated sensitivity to CDC was demonstrated in cells lacking the p65 subunit of NF-κB or the IκB kinases IKKα or IKKβ, and in cells treated with p65 small interfering RNA. Pretreatment with the IKK...

Journal: :Journal of immunology 2009
Andrew W Pawluczkowycz Frank J Beurskens Paul V Beum Margaret A Lindorfer Jan G J van de Winkel Paul W H I Parren Ronald P Taylor

The CD20 mAb ofatumumab (OFA) is more effective than rituximab (RTX) in promoting complement-dependent cytotoxicity (CDC) of B cells via the classical pathway (CP) of complement. CP activation is initiated by C1q binding to cell-bound IgG. Therefore, we examined the role of C1q in the dynamics of complement activation and CDC of B cell lines and primary cells from patients with chronic lymphocy...

2013
Chie Kato Atsuhiko Kato Kenji Adachi Etsuko Fujii Kaori Isobe Takeshi Watanabe Tsuneo Ito Masami Suzuki

Some anticancer therapeutic antibodies are designed to act through complement-dependent cytotoxicity (CDC). It has been reported that there are many membrane complement regulatory proteins (mCRPs) that inhibit CDC. In the present study, we examined the expression of two mCRPs, the complement receptor 1-related gene/protein Y (Crry) and the decay-accelerating factor CD55, in three normal rats by...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید